Patient-derived induced pluripotent stem cells for precision modelling of monogenic beta cell disorders
-
By
-
Lily Deng
-
Mansa Krishnamurthy
-
June 3, 2026
-
Clinical Scorecard: Induced Pluripotent Stem Cells from Patients for Precision Modeling of Monogenic Disorders Affecting Beta Cell Function
At a Glance
| Category | Detail |
|---|
| Condition | Monogenic disorders of beta cell dysfunction |
| Key Mechanisms | Pathogenic variants in single genes affecting beta cell development, insulin secretion, and stimulus secretion coupling. |
| Target Population | Patients with monogenic beta cell disorders such as MODY and congenital hyperinsulinism. |
| Care Setting | Research laboratories utilizing induced pluripotent stem cell technology. |
Key Highlights
- iPSCs can be derived from patients with novel genetic variants.
- iPSC-derived SC-islets model key aspects of human beta cell development.
- Studies demonstrate defects in insulin secretion and beta cell maturation.
- iPSC technology allows for patient-specific 'disease in a dish' models.
- Challenges include incomplete functional maturation of SC-islets.
Guideline-Based Recommendations
Diagnosis
- Precise molecular diagnosis is essential for therapeutic implications.
Management
- Genotype-guided treatment strategies differ from conventional approaches.
Monitoring & Follow-up
- Continued refinement of iPSC models is necessary to capture adult beta cell physiology.
Risks
- Variability across differentiation protocols may affect outcomes.
Patient & Prescribing Data
Individuals with monogenic beta cell disorders.
iPSC-derived models facilitate the evaluation of targeted therapies.
Clinical Best Practices
- Utilize iPSC-derived SC-islets for mechanistic studies of beta cell disorders.
- Combine genome editing with iPSC models to create isogenic controls.
- Focus on expanding modeling efforts beyond well-studied disorders.
Related Resources & Content
